Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-Month results from a randomized controlled study-Response

Affiliations

¹ State Key Laboratory of Ophthalmology, Retina Division, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
² Scientific supporting department, Bothwin Clinical Study Consultant, Shanghai, China.

Comment

Songshan Li et al. Clin Exp Ophthalmol. 2019 Jul.

. 2019 Jul;47(5):685-686.

doi: 10.1111/ceo.13507. Epub 2019 Apr 15.

¹ State Key Laboratory of Ophthalmology, Retina Division, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
² Scientific supporting department, Bothwin Clinical Study Consultant, Shanghai, China.

No abstract available

Comment in

Ophthalmology Letterbox.
Smith JR. Smith JR. Clin Exp Ophthalmol. 2021 Apr;49(3):225-227. doi: 10.1111/ceo.13908. Epub 2021 Mar 9. Clin Exp Ophthalmol. 2021. PMID: 33686745 No abstract available.

Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study.
Li S, Ding X, Sun L, Zhao X, Zhang A, Lyu C, Liu B, Zhang J, Jin C, Lu L. Li S, et al. Clin Exp Ophthalmol. 2019 Mar;47(2):250-258. doi: 10.1111/ceo.13424. Epub 2018 Nov 22. Clin Exp Ophthalmol. 2019. PMID: 30345611 Clinical Trial.
Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-Month results from a randomized controlled study-Comment.
Cao J, Tan W, Tian C. Cao J, et al. Clin Exp Ophthalmol. 2019 Jul;47(5):684-685. doi: 10.1111/ceo.13505. Epub 2019 Apr 15. Clin Exp Ophthalmol. 2019. PMID: 30924251 No abstract available.